Jost S, Rafflenbeul W, Deckers J, Wiese B, Hecker H, Nikutta P, Lippolt P, Lichtlen P
Department of Cardiology, Hannover Medical School, FRG.
Eur J Epidemiol. 1992 May;8 Suppl 1:107-19. doi: 10.1007/BF00145361.
Animal experiments suggest an inhibitory effect of calcium entry blockers on arterial calcinosis and the formation of atherosclerotic plaques. Experiments with isolated tissues suggest various mechanisms for an antiatherosclerotic effect of calcium entry blockers. INTACT, the International Nifedipine Trial on Antiatherosclerotic Therapy, is the first study investigating, with a prospective, placebo-controlled, randomized, double-blind design, the influence of a calcium entry blocker (nifedipine 80 mg/day) on the progression of coronary atherosclerosis in patients with proven coronary artery disease. Study endpoints were changes of established coronary stenoses (diameter reduction greater than or equal to 20%), as well as the formation of new stenoses as documented by coronary angiography. Standardized coronary angiograms were taken before and after a treatment period of 3 years. The angiograms were quantitatively analyzed with the computer-assisted edge detection system CAAS. Of the 425 patients included in the study, 282 patients (134 on nifedipine and 148 on placebo) revealed no protocol violations. In the inclusion angiograms of these patients, 893 coronary stenoses were detected which were not significantly influenced in their development by nifedipine. However, 196 entirely new coronary lesions, 185 stenoses and 11 occlusions, were found in the follow-up angiograms. There were 78 lesions in 54 patients (40%) on nifedipine (0.58 new lesions/patient) and 118 lesions in 73 patients (49%; n.s.) on placebo (0.8 new lesions/patient; p = 0.031). In two other studies on the inhibiting effect of dihydropyridine calcium entry blockers on the progression of coronary artery disease in man defining angiographic endpoints, the drugs were also shown to reduce the number of newly formed significant coronary lesions. If further trials in man confirm a protective role of calcium entry blockers against the formation of atherosclerotic coronary lesions, a new strategy in the prevention of coronary artery disease has to be considered.
动物实验表明,钙通道阻滞剂对动脉钙化和动脉粥样硬化斑块的形成具有抑制作用。对离体组织进行的实验提示了钙通道阻滞剂抗动脉粥样硬化作用的多种机制。“国际硝苯地平抗动脉粥样硬化治疗试验(INTACT)”是第一项采用前瞻性、安慰剂对照、随机、双盲设计,研究钙通道阻滞剂(硝苯地平80毫克/天)对已确诊冠心病患者冠状动脉粥样硬化进展影响的研究。研究终点为既定冠状动脉狭窄(直径缩小大于或等于20%)的变化,以及冠状动脉造影记录的新狭窄的形成。在3年治疗期前后拍摄标准化冠状动脉造影。使用计算机辅助边缘检测系统CAAS对造影进行定量分析。在纳入研究的425例患者中,282例患者(134例服用硝苯地平,148例服用安慰剂)未出现违反方案的情况。在这些患者的纳入造影中,检测到893处冠状动脉狭窄,其发展未受到硝苯地平的显著影响。然而,在随访造影中发现了196处全新的冠状动脉病变——185处狭窄和11处闭塞。服用硝苯地平的54例患者(40%)中有78处病变(0.58处新病变/患者),服用安慰剂的73例患者(49%;无显著差异)中有118处病变(0.8处新病变/患者;p = 0.031)。在另外两项关于二氢吡啶类钙通道阻滞剂对人类冠状动脉疾病进展抑制作用的研究中,将血管造影终点作为指标,结果也显示这些药物减少了新形成的显著冠状动脉病变的数量。如果在人体进行的进一步试验证实钙通道阻滞剂对动脉粥样硬化性冠状动脉病变的形成具有保护作用,那么就必须考虑预防冠状动脉疾病的新策略。